When reviewing lipid panels in patients on semaglutide, providers should consider these potential improvements when assessing cardiovascular risk
Available at: American Society for Reproductive Medicine (ASRM)
Shorter showers and warm (not hot) water are best
10.1007/s10787-017-0358-8 [DOI] [PubMed] [Google Scholar] Berkopic Cesar L., Gojkovic S., Krezic I., Malekinusic D., Zizek H., Batelja Vuletic L., et al
Semaglutide is the most widely prescribed option and has the longest safety track record
Navigator Study Group, Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamas G, Tognoni G, Tuomilehto J, Villamil AS, Vozar J, Califf RM
